Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jesse Alt

Showing results (71-80 of 78) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 78 results.
Science (New York, N.Y.)|November 9, 2019
Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasionRobert D Leone, Liang Zhao, Judson M Englert, et al.
Journal of Medicinal Chemistry|August 1, 2017
N-(Pivaloyloxy)alkoxy-carbonyl Prodrugs of the Glutamine Antagonist 6-Diazo-5-oxo-l-norleucine (DON) as a Potential Treatment for HIV Associated Neurocognitive DisordersMichael T Nedelcovych, Lukáš Tenora, Boe-Hyun Kim, et al.
The Journal of Infectious Diseases|February 26, 2026
Safety, tolerability, and pharmacokinetics of 6-diazo-5-oxo-L-norleucine (DON) in Malawian adults with and without malaria: a Phase I dose-escalation clinical trialBrittany A Riggle, Athanasios Chamzas, Mathangi Gopalakrishnan, et al.
Journal of Medicinal Chemistry|February 4, 2022
Thieno[2,3-<i>d</i>]pyrimidine-Based Positive Allosteric Modulators of Human Mas-Related G Protein-Coupled Receptor X1 (MRGPRX1)Ilyas Berhane, Niyada Hin, Ajit G Thomas, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 26, 2016
Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancerAmira Elgogary, Qingguo Xu, Brad Poore, et al.
Science Advances|November 16, 2022
Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrugRana Rais, Kathryn M Lemberg, Lukáš Tenora, et al.
Cancer Immunology Research|May 3, 2024
Metabolic Reprogramming of Tumor-Associated Macrophages Using Glutamine Antagonist JHU083 Drives Tumor Immunity in Myeloid-Rich Prostate and Bladder CancersMonali Praharaj, Fan Shen, Alex J Lee, et al.
PNAS Nexus|January 30, 2023
Topical SCD-153, a 4-methyl itaconate prodrug, for the treatment of alopecia areataJerry Tsai, Sadakatali Gori, Jesse Alt, et al.
Pageof 8

Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
Science (New York, N.Y.)|November 9, 2019
Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasionRobert D Leone, Liang Zhao, Judson M Englert, et al.
Journal of Medicinal Chemistry|August 1, 2017
N-(Pivaloyloxy)alkoxy-carbonyl Prodrugs of the Glutamine Antagonist 6-Diazo-5-oxo-l-norleucine (DON) as a Potential Treatment for HIV Associated Neurocognitive DisordersMichael T Nedelcovych, Lukáš Tenora, Boe-Hyun Kim, et al.
The Journal of Infectious Diseases|February 26, 2026
Safety, tolerability, and pharmacokinetics of 6-diazo-5-oxo-L-norleucine (DON) in Malawian adults with and without malaria: a Phase I dose-escalation clinical trialBrittany A Riggle, Athanasios Chamzas, Mathangi Gopalakrishnan, et al.
Journal of Medicinal Chemistry|February 4, 2022
Thieno[2,3-<i>d</i>]pyrimidine-Based Positive Allosteric Modulators of Human Mas-Related G Protein-Coupled Receptor X1 (MRGPRX1)Ilyas Berhane, Niyada Hin, Ajit G Thomas, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 26, 2016
Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancerAmira Elgogary, Qingguo Xu, Brad Poore, et al.
Science Advances|November 16, 2022
Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrugRana Rais, Kathryn M Lemberg, Lukáš Tenora, et al.
Cancer Immunology Research|May 3, 2024
Metabolic Reprogramming of Tumor-Associated Macrophages Using Glutamine Antagonist JHU083 Drives Tumor Immunity in Myeloid-Rich Prostate and Bladder CancersMonali Praharaj, Fan Shen, Alex J Lee, et al.
PNAS Nexus|January 30, 2023
Topical SCD-153, a 4-methyl itaconate prodrug, for the treatment of alopecia areataJerry Tsai, Sadakatali Gori, Jesse Alt, et al.
Pageof 8